6727027F-4BAB-41ED-87F3-ECC7B1718ECF
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.19710906701708278
- age_years
- 63
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.637
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.597
- IL6_JAK_STAT3_SIGNALING+0.560
- ALLOGRAFT_REJECTION+0.553
- INFLAMMATORY_RESPONSE+0.534
- INTERFERON_GAMMA_RESPONSE+0.527
- HYPOXIA+0.493
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.490
- TNFA_SIGNALING_VIA_NFKB+0.486
- INTERFERON_ALPHA_RESPONSE+0.480
Top 10 suppressed
- KRAS_SIGNALING_DN-0.358
- SPERMATOGENESIS-0.343
- PANCREAS_BETA_CELLS-0.342
- HEDGEHOG_SIGNALING-0.004
- WNT_BETA_CATENIN_SIGNALING+0.010
- MYOGENESIS+0.088
- MITOTIC_SPINDLE+0.111
- BILE_ACID_METABOLISM+0.153
- E2F_TARGETS+0.177
- HEME_METABOLISM+0.179
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A219A5D7-C67B-4CF0-860A-78ADEB56A13D | — | — | 0.980 |
| 2 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.975 |
| 3 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.966 |
| 4 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.963 |
| 5 | CD273289-C865-4902-801B-E32CA866EB4B | — | — | 0.963 |
| 6 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.962 |
| 7 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.960 |
| 8 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.959 |
| 9 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.957 |
| 10 | 15FB165D-6751-4894-A904-C77EA723CFCB | — | — | 0.956 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.637 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.597 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.553 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.534 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.527 | Idelalisib | — uncovered |
| HYPOXIA | 0.493 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.486 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| APOPTOSIS | 0.470 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.461 | Idelalisib | — uncovered |
| COMPLEMENT | 0.449 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.425 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.422 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.416 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.398 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.386 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.377 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.369 | Inavolisib | — uncovered |